SELECT Trial (Semaglutide)
(This is the most exciting news since statins for the obese?)
~17,000 obese. Half of them on 2.4 mg Semaglutide weekly. Not diabetic. 40 months follow-up.
The primary outcome:
Composite of CV death, nonfatal MI, and nonfatal stroke, for semaglutide vs. placebo, was: 6.5% vs. 8.0% (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.72-0.90, p < 0.001).
Secondary outcomes for semaglutide vs. placebo:
- CV death: 2.5% vs. 3.0% (HR 0.85, 95% CI 0.71-1.01, p = 0.07)
- CV death or HF hospitalization: 3.4% vs. 4.1% (HR 0.82, 95% CI 0.71-0.96)
- All-cause death: 4.3% vs. 5.2% (HR 0.81, 95% CI 0.71-0.93)
- Nonfatal MI: 2.7% vs. 3.7% (HR 0.72, 95% CI 0.61-0.85)
Additional outcomes for semaglutide vs. placebo:
- HbA1c ≥6.5%: 3.5% vs. 12.0% (HR 0.27, 95% CI 0.24-0.31)
- Change in systolic blood pressure: –3.8 vs. –0.5 mm Hg
- Mean change in body weight at 104 weeks: –9.4% vs. –0.9%





